Charles C. Williams, Jr, MD

Where You Are:

Charles C. Williams, Jr, MD

Medical Oncology

For Consultation Requests or Referrals: (813) 745-3050

 
 

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  University of South Florida - Hematology/Oncology

RESIDENCY:
          •  University of South Florida - Chief Medical Resident
          •  University of South Florida - Medicine

MEDICAL SCHOOL:
          •  University of Pittsburgh - MD

  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.

  • Quinn GP, Pratt CL, Bryant-George K, Caraway VD, Paternoster B, Roldan T, Shaffer A, Shimizu CO, Vaughn EJ, Williams C, Bepler G. Lung cancer patients' decisions about clinical trials and the theory of planned behavior. J Cancer Educ. 2011 Dec;26(4):641-648. Pubmedid: 20949381.

  • Simon GR, Ilaria RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-1241. Pubmedid: 21431416. Pmcid: PMC3215883.

  • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar;6(3):553-558. Pubmedid: 21289520.

  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.

  • Faul LA, Jim HS, Williams C, Loftus L, Jacobsen PB. Relationship of stress management skill to psychological distress and quality of life in adults with cancer. Psychooncology. 2010 Jan;19(1):102-109. Pubmedid: 19253915.

  • Bevers TB, Anderson BO, Bonaccio E, Buys S, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009 Nov;7(10):1060-1096. Pubmedid: 19930975.

  • Silva C, Wood JR, Salvador L, Zhang Z, Kostetskii I, Williams CJ, Strauss JF. Expression profile of male germ cell-associated genes in mouse embryonic stem cell cultures treated with all-trans retinoic acid and testosterone. Mol Reprod Dev. 2009 Jan;76(1):11-21. Pubmedid: 18425777.

  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.

  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.

  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.

  • Melchert M, Williams C, List A. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome. Leukemia. 2007 Jul;21(7):1576-1578. Pubmedid: 17392815.

  • Quinn G, Bell B, Bell M, Caraway V, Conforte D, Graci L, Powell-Stafford V, Sapp A, Shimizu C, Vaughn E, Williams C, Bepler G. The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol. 2007 Mar;2(3):191-196. Pubmedid: 17410041.

  • Dobbs D, Hanson L, Zimmerman S, Williams C, Munn J. Hospice Attitudes among Assisted Living and Nursing Home Administrators, and the Long-Term Care Hospice Attitudes Scale. J Palliat Med. 2006 Dec;9(6):1388-1400. Pubmedid: 17187547.

  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.

  • Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug;12(15):4645-4651. Pubmedid: 16899614.

  • Frost M, Slezak J, Tran N, Williams C, Johnson J, Woods J, Petty P, Donohue J, Grant C, Sloan J, Sellers T, Hartmann L. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005 Nov;23(31):7849-7856. Pubmedid: 16204003.

  • Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology-Basel. 2005 Sep;68(4-6):382-390. Pubmedid: 16020967.

  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.

  • Barnett E, Williams C, Moore L, Chen F. Social class and heart disease mortality among African Americans. Ethn Dis. 2002;12(4):S3-76-81. Pubmedid: 12477160.

  • Kim S, McLeod J, Williams C, Hepler N. Prevention validation and accounting platform: a framework for establishing accountability and performance measures of substance abuse prevention programs. J Drug Educ. 2000;30(1):1-143. Pubmedid: 10893910.

  • Williams C, Iqbal S, Zawacki C, Yu D, Brown M, Herman W. Effect of selective screening for gestational diabetes. Diabetes Care. 1999 Mar;22(3):418-421. Pubmedid: 10097921.

  • Antonia S, Wagner, Jr. H, Williams, Jr. C, Alberts W, Hubbell D, Robinson L, Hilstro J, Ruckdeschel J. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin Oncol. 1995 Aug;22(4 Suppl 9):34-37. Pubmedid: 7644926.

  • Greene J, Sandin R, Williams Jr. C, Beatty A. Cancer patients with lesions of the hands: is it a metastasis or an infection?. Cancer Control. 1994;1(2):168-170.

  • Luria L, Proper S, Burnett S, Williams Jr. C, Fenske N. An anatomical basis for prognosis of malignant melanoma. Plast Reconstr Surg. 1992;90(2):263-269.

  • Williams, Jr. C, Ruckdeschel J. Management of disseminated non-small cell lung cancer. In: Roth J, Ruckdeschel J, Weisenburger T, et al, eds. Thoracic Oncology. II ed. Philadelphia, PA: W.B. Saunders; 1995;181-187.

  • Simon G, Ruckdeschel J, Williams C, Cantor A, Antonia S, Haura E, Rocha C, Chiappori A, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 10(5):388-395. Pubmedid: 14581894.

  • Garland L, Ruckdeschel J, Wagner, Jr. H, Williams, Jr. C, Shaw G, Antonia S, Heise M, Hilstro J, Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant, metastatic non-small cell lung cancer. In: Johnson, Klastersky, eds. Taxanes in Lung Cancer Therapy. New York, NY: Marcel Dekker; 1998;117-126.

Dr. Charles Williams completed medical school at the University of Pittsburgh.  He completed an internal medicine residency program and a clinical fellowship in medical oncology-hematology at the University of South Florida in Tampa.   

He is a senior member of the Thoracic Oncology Program here at Moffitt Cancer Center, where he has been practicing for 25 years – ever since these doors were first opened as a brand new treatment center – and is Board Certified in Medical Oncology. 

Dr. Williams’ special interests include the treatment of all types of lung cancer.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions